Patents Assigned to Chugai Seiyaku Kabushiki Kaisha
-
Patent number: 11667713Abstract: The present inventors discovered novel multispecific antigen-binding molecules with excellent cellular cytotoxicity, which comprise a first domain comprising a first antigen variable region which binds to DLL3 and a second domain comprising a second antigen variable region which binds to T cell receptor complex. The present inventors prepared further bispecific antibodies, and assessed their T cell-dependent cell cytotoxicity (TDCC), and found that they also show strong TDCC activity. Since the molecules/antibodies of the present invention show a strong cytotoxicity against cells expressing DLL3, novel pharmaceutical compositions comprising the molecules/antibodies for treating or preventing various cancers associated with DLL3 can be provided.Type: GrantFiled: December 28, 2018Date of Patent: June 6, 2023Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Shogo Kamikawaji, Yasuko Kinoshita, Shinya Ishii
-
Patent number: 11667720Abstract: The present application concerns methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.Type: GrantFiled: March 1, 2023Date of Patent: June 6, 2023Assignees: Hoffmann-La Roche Inc., Chugai Seiyaku Kabushiki KaishaInventors: Xiaoping Zhang, Kimio Terao
-
Patent number: 11661579Abstract: Methods of culturing cells capable of producing desired proteins to obtain the proteins by use of a medium from which biological components are excluded as much as possible are provided. Specifically, a culture method characterized by culturing while maintaining a specific amino acid in a culture solution at a high concentration, and a cell culture fed-batch medium for use in the method are provided.Type: GrantFiled: March 8, 2019Date of Patent: May 30, 2023Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Satoshi Katayama, Shouhei Kishishita, Kunihiko Kodaira, Makoto Sadamitsu, Yoshinori Takagi, Hiroki Matsuda
-
Patent number: 11660340Abstract: The present invention provides methods for treating or preventing cancer by administering an anticancer agent and an antigen-binding molecule comprising a domain that binds to a molecule expressed on the surface of a cell having an immune response-suppressing function and a T cell receptor complex-binding domain. The present invention also provides pharmaceutical compositions for treating or preventing cancer, each comprising a combination of the anticancer agent and the antigen-binding molecule.Type: GrantFiled: November 17, 2016Date of Patent: May 30, 2023Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Toshiaki Tsunenari, Yutaka Matsuda, Taro Miyazaki, Kenji Taniguchi
-
Publication number: 20230159648Abstract: The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions. The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions.Type: ApplicationFiled: January 12, 2023Publication date: May 25, 2023Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Shinya Ishii, Atsuhiko Maeda, Mika Sakurai, Tetsuo Kojima, Tatsuhiko Tachibana, Hirotake Shiraiwa, Hiroyuki Tsunoda, Yoshinobu Higuchi
-
Publication number: 20230159658Abstract: An objective of the present invention is to provide an effective pharmaceutical composition or a dosage regimen for preventing and/or treating bleeding, a disease accompanying bleeding, or a disease caused by bleeding. The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes (a) blood coagulation factor IX and/or activated blood coagulation factor IX and (b) blood coagulation factor X and/or activated blood coagulation factor X according to a given dosage regimen, bleeding, a disease accompanying bleeding, or a disease caused by bleeding can be prevented and/or treated more effectively.Type: ApplicationFiled: January 19, 2023Publication date: May 25, 2023Applicants: Chugai Seiyaku Kabushiki Kaisha, F. Hoffmann-La Roche AGInventors: Koichiro Yoneyama, Christophe Schmitt
-
Publication number: 20230152280Abstract: The present disclosure provides an analysis method for measuring the content of light chain-exchanged molecules in a composition containing a multi-specific antigen-binding molecule. The analysis method of the present disclosure includes the steps of: treating a composition comprising a multi-specific antigen-binding molecule and preparing a plurality of types of F(ab) fragments; and measuring the F(ab) fragments by a separation method based on electric charge or hydrophobic interactions and determining the content (content ratio) of each fragment.Type: ApplicationFiled: April 1, 2021Publication date: May 18, 2023Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Motohiko Sato, Hiroko Murata
-
Patent number: 11649262Abstract: It was discovered that, by preparing an Fc region of an Fc region-containing polypeptide in which the first polypeptide chain of the Fc region binds to a Protein A resin, but the second polypeptide chain of the Fc region does not bind to the resin or shows weak binding to it, the amount of the Fc region-containing polypeptide bound per volume of the resin is increased, and more efficient purification of the above-mentioned Fc region-containing polypeptide is possible.Type: GrantFiled: December 27, 2016Date of Patent: May 16, 2023Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Nobuyuki Tanaka, Rumiko Momose
-
Patent number: 11649293Abstract: The present invention provides methods for producing antibodies against peptides, proteins, or such to which immune tolerance is easily established, by using antigen-binding molecules comprising a domain that binds to a molecule expressed on the surface of a cell having an immune response-suppressing function and a T cell receptor (TCR) complex-binding domain. The present invention also provides pharmaceutical compositions for use in combination with therapeutic vaccines and agents for enhancing a humoral immune response, each comprising the antigen-binding molecules as active ingredients.Type: GrantFiled: November 18, 2016Date of Patent: May 16, 2023Assignee: Chugai Seiyaku Kabushiki KaishaInventor: Tomoyuki Igawa
-
Publication number: 20230147840Abstract: An antigen-binding molecule comprising a first antigen-binding moiety that is capable of binding to CD3 and CD137 (4-1BB), but does not bind to CD3 and CD137 at the same time (i.e. dual-binding to CD3 and CD137 but not simultaneously); and a second antigen-binding moiety capable of binding to a molecule specifically expressed in a cancer tissue, specifically Glypican-3 (GPC3) is provided. Due to the dual binding to CD3 and CD137 but not simultaneously and with fine-tuned binding kinetics, and the binding to GPC3, the multispecific antigen-binding molecule express strong cytotoxic activity for cancer cells with reduced adverse effects. Further, by adapting antibody engineering technologies and a molecular format design (including charged mutations in the framework region and/or constant region, VH/VL exchanged, and Fc region selection), the multispecific antigen-binding molecule with favorable stability, manufacturability/producibility and structural homogeneity is provided.Type: ApplicationFiled: March 30, 2021Publication date: May 11, 2023Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Sotaro Naoi, Shu Feng, Siok Wan Gan
-
Publication number: 20230142119Abstract: A compound represented by the general Formula (I) below, or a salt or solvate thereof, which is useful as an ALK inhibitor, and is useful for prophylaxis or treatment of a disease accompanied by abnormality in ALK, for example, cancer, cancer metastasis, depression or cognitive function disorder: (meanings of the symbols that are included in the formula are as given in the specification).Type: ApplicationFiled: July 8, 2022Publication date: May 11, 2023Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Kazutomo KINOSHITA, Kohsuke ASOH, Noriyuki FURUICHI, Toshiya ITO, Hatsuo KAWADA, Nobuya ISHII, Hiroshi SAKAMOTO, WooSang HONG, MinJeong PARK, Yoshiyuki ONO, Yasuharu KATO, Kenji MORIKAMI, Takashi EMURA, Nobuhiro OIKAWA
-
Publication number: 20230146730Abstract: The invention provides biomarkers for predicting the response to checkpoint inhibitors. The inventors demonstrate that a PD-1/PD-L1 inhibitor exerts antitumor activity against tumor with low PD-L1 expression and immune-desert phenotype through blocking PD-L1 in the lymph nodes. The invention provides novel combinations of intratumoral markers for antigen cross-presenting cells and T cell chemokines which are expected to be superior efficacy-predicting biomarkers compared to existing methods.Type: ApplicationFiled: March 19, 2021Publication date: May 11, 2023Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Toshiki Iwai, Masamichi Sugimoto
-
Publication number: 20230140797Abstract: The present invention provides antigen-binding molecules containing (i) an antigen-binding domain whose antigen-binding activity varies depending on ion concentration conditions, (ii) an Fc?R-binding domain having Fc? RIIb-selective binding activity, and (iii) an FcRn-binding domain having FcRn-binding activity under an acidic pH range condition, and methods of decreasing plasma antigen concentration as compared to before administering the molecule, which include the step of administering the molecule.Type: ApplicationFiled: June 30, 2022Publication date: May 4, 2023Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Atsuhiko Maeda, Yuki Iwayanagi, Kenta Haraya, Hitoshi Katada, Shojiro Kadono, Futa Mimoto
-
Patent number: 11633402Abstract: A compound represented by the following general formula (I) [the symbol in the formula are as defined in the description], a salt thereof, or the like is a RET inhibitor or RET tyrosine kinase inhibitor that can he used as an agent for the prevention or treatment of disorders including cancers and cancer metastasis having mutations in RET.Type: GrantFiled: April 22, 2020Date of Patent: April 25, 2023Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tatsushi Kodama, Hiroshi Sakamoto, Toshiyuki Tsukaguchi
-
Publication number: 20230118024Abstract: The antibodies of the present invention have specific binding activity to HLA-DQ2.5 and may have binding activity to HLA-DQ2.2 and/or HLA-DQ7.5, but substantially no binding activity to HLA-DQ8, HLA-DQ5.1, HLA-DQ6.3, HLA-DQ7.3, HLA-DR, HLA-DP, or a complex of the invariant chain (CD74) and HLA-DQ2.5. The antibodies bind to HLA-DQ2.5 in the presence of a gluten peptide such as gliadin, i.e., bind to HLA-DQ2.5 forming a complex with the gluten peptide. The antibodies have neutralizing activity against the binding between HLA-DQ2.5 and TCR, and thus block the interaction between HLA-DQ2.5 and an HLA-DQ2.5-restricted CD4+ T cell. The antibodies do not undergo rapid internalization mediated by the invariant chain.Type: ApplicationFiled: October 27, 2022Publication date: April 20, 2023Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Yuu Okura, Noriyuki Takahashi, Takashi Tsushima, Zulkarnain Harfuddin, Akihiko Mizoroki
-
Publication number: 20230121511Abstract: Multispecific antigen-binding molecule capable of binding to multiple different antigens, but do not non-specifically crosslink two or more immune cells such as T cells are provided. Methods for producing or enriching a preferred structural form of such multispecific antibody protein, and method for eliminating disulfide heterogeneity of such multispecific antibody proteins are provided. In addition, conformation-specific antibodies that specifically recognize the preferred form of multispecific antibody proteins, and use of the conformation-specific antibodies are provided.Type: ApplicationFiled: March 31, 2021Publication date: April 20, 2023Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Vishnu Priyanka Reddy Chichili, Chai Ling Pang, Tatsuya Kawa, Shu Feng, Siok Wan Gan, Noriyuki Takahashi, Masaru Muraoka
-
Patent number: 11622969Abstract: The present application concerns methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.Type: GrantFiled: May 9, 2022Date of Patent: April 11, 2023Assignees: Hoffmann-La Roche Inc., Chugai Seiyaku Kabushiki KaishaInventors: Xiaoping Zhang, Kimio Terao
-
Publication number: 20230105990Abstract: An improved solubility of a pharmaceutical composition or formulation containing a large amount of 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile or a salt thereof can be achieved by forming granules of the compound or salt thereof and allowing the granules to be present together with a disintegrating agent.Type: ApplicationFiled: August 26, 2022Publication date: April 6, 2023Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Takashi TOMIMATSU, Kensuke OKAZAKI, Yumi OGAWA, Takahiro YAMAMURA
-
Patent number: 11612562Abstract: An objective of the present invention is to provide stable antibody-containing formulations which are suitable for subcutaneous administration and in which aggregation formation is suppressed during long-term storage. The present inventors discovered that a significant stabilization effect was achieved by using an acidic amino acid, aspartic acid or glutamic acid as a counter ion species in histidine buffer or tris(hydroxymethyl)aminomethane, specifically by using histidine-aspartate buffer or histidine-glutamate buffer, or tris(hydroxymethyl)aminomethane-aspartate or tris(hydroxymethyl)aminomethane-glutamate as a buffer. The present inventors also discovered that a significant stabilization effect was achieved by using an acidic amino acid, aspartic acid or glutamic acid, as a counter ion species to a basic amino acid such as arginine, specifically by using arginine-aspartate or arginine-glutamate.Type: GrantFiled: June 14, 2018Date of Patent: March 28, 2023Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Chifumi Moriyama
-
Patent number: 11612149Abstract: The present invention provides genetically modified non-human animals which are deficient in at least one or more types of CD3 genes selected from the group consisting of endogenous CD3?, CD3?, and CD3? in its genome and functionally express at least one or more types of human CD3 genes selected from the group consisting of human CD3?, CD3?, and CD3?. In the genetically modified non-human animals of the present invention, mature T cell differentiation and production can take place, and immunocompetent cells including T cells can exert their functions. The genetically modified non-human animals of the present invention enable efficient evaluation and screening in the development of therapeutic agents and therapeutic methods that use human CD3-mediated targeted drugs.Type: GrantFiled: July 8, 2016Date of Patent: March 28, 2023Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Koichi Jishage, Otoya Ueda, Naoko Wada, Takahiro Ishiguro, Yasuko Kinoshita